Payment overview · 2025
General Payments
$64,051.04
121 reported records · 15 companies
Healthcare provider profile · identity verified
Ada Stewart, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COLUMBIA, SC · NPI 1750333050
Verified facts
What the public records show
CMS Open Payments records show Ada Stewart, MD received $64,051.04 in general payments during 2025 across 121 reported records.
Gen-Probe, Inc. accounted for 33.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Descovy.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Descovy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Isentress by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gen-Probe, Inc. | Unresolved — no canonical attribution shown | $21,709.03 | 33.9% | 4 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $20,090.15 | 31.4% | 54 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18,328.59 | 28.6% | 33 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $3,335.60 | 5.2% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $168.13 | 0.3% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $142.19 | 0.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.14 | 0.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.25 | 0.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.88 | 0.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.83 | 0.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.33 | 0.0% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $17.24 | 0.0% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.70 | 0.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.32 | 0.0% | 1 | 2025 |
| Optos, Inc. | Unresolved — no canonical attribution shown | $13.66 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,470.00 | 9 |
| Consulting Fee | $21,600.00 | 2 |
| Travel and Lodging | $13,095.79 | 26 |
| Food and Beverage | $3,871.59 | 83 |
| Entertainment | $13.66 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APTIMA Normalized: aptima |
Device | Gen-Probe, Inc., Hologic Sales and Service, LLC | $24,552.04 | 13 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $17,532.14 | 22 | 2025 |
Source payment records
|
|||||
| Descovy Normalized: descovy |
Drug | Gilead Sciences, Inc. | $7,009.41 | 10 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $5,575.14 | 7 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $5,240.59 | 5 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $207.84 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $168.13 | 5 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $161.99 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $142.19 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $58.25 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $58.25 | 3 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $51.59 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.88 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $42.84 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.59 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| NFC-700 Normalized: nfc 700 |
Device | Optos, Inc. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| OCT OPHTHALMOSCOPE Normalized: oct ophthalmoscope |
Device | Optos, Inc. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| PANORAMIC OPHTHALMOSCOPE Normalized: panoramic ophthalmoscope |
Device | Optos, Inc. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Descovy descovy |
2025 | Descovy | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
149 | 19 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 205 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 174 | 48 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 149 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 28 |
| Gabapentin | Gabapentin | 81 | 21 |
| Furosemide | Furosemide | 69 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 20 |
| Metformin Hcl | Metformin Hcl | 60 | 17 |
| Omeprazole | Omeprazole | 58 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 58 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 56 | 11 |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Potassium Chloride | Potassium Chloride | 54 | suppressed |
| Ozempic | Semaglutide | 50 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 16 |
| Descovy | Emtricitabine/Tenofov Alafenam | 47 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 47 | 12 |
| Losartan Potassium | Losartan Potassium | 46 | 13 |
| Meloxicam | Meloxicam | 46 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Carvedilol | Carvedilol | 35 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 35 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 14 |
| Azithromycin | Azithromycin | 24 | 14 |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 23 | suppressed |
| Tivicay | Dolutegravir Sodium | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Lisinopril | Lisinopril | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 13 |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Complera | Emtricita/Rilpivirine/Tenof Df | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Isentress | Raltegravir Potassium | 12 | suppressed |
| Lamivudine-Zidovudine | Lamivudine/Zidovudine | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 11 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $64,051.04 · 121 records | Gen-Probe, Inc. | ABRYSVO, APRETUDE, APTIMA, CABENUVA, CLOTTRIEVER BOLD CATHETER, COMIRNATY, Cologuard Collection Kit, DOVATO, Descovy, Epclusa, FREESTYLE LIBRE 3, MAVYRET, MOUNJARO, NFC-700, OCT OPHTHALMOSCOPE, PANORAMIC OPHTHALMOSCOPE, PIFELTRO, PREVNAR 20, RUKOBIA, STRENSIQ, THINPREP 2000 PROCESSOR, VRAYLAR, Veozah, Wegovy, Yeztugo, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Descovy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error